Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real‐world setting-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real‐world setting

Published:2022-08-12 Issue:10 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Singh Amritpal¹,Al‐Kali Aref¹^ORCID,Foran James M.²,Elliott Michelle A.¹^ORCID,Begna Kebede¹^ORCID,Badar Talha¹^ORCID,Khera Nandita³,Fleti Farah¹,Abdelmagid Maymona¹,Reichard Kareen K.⁴,Ketterling Rhett P.⁴,Pardanani Animesh¹^ORCID,Gangat Naseema¹^ORCID,Tefferi Ayalew¹^ORCID

Affiliation:

1. Divisions of Hematology Rochester Mayo Clinic Rochester Minnesota USA

2. Jacksonville Mayo Clinic Rochester Minnesota USA

3. Scottsdale Mayo Clinic Rochester Minnesota USA

4. Division of Hematopathology, Rochester Mayo Clinic Rochester Minnesota USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26672

Reference10 articles.

1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

2. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach

3. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

4. WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations

5. Primary Myelodysplastic Syndromes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q);British Journal of Haematology;2023-12-11

2. Management of patients with lower-risk myelodysplastic syndromes;Blood Cancer Journal;2022-12-14

3. Lenalidomide;Reactions Weekly;2022-10-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3